您的购物车当前为空
别名 沃瑟妥珠单抗, SGN-70
Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) 是靶向 CD70 抗体的单克隆抗体。Vorsetuzumab 具有抗癌活性,能够加强肾癌细胞巨噬相关吞噬作用,抑制 Burkitt 淋巴瘤。

为众多的药物研发团队赋能,
让新药发现更简单!
Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) 是靶向 CD70 抗体的单克隆抗体。Vorsetuzumab 具有抗癌活性,能够加强肾癌细胞巨噬相关吞噬作用,抑制 Burkitt 淋巴瘤。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 2,320 | 现货 | |
| 5 mg | ¥ 5,490 | 现货 | |
| 10 mg | ¥ 7,480 | 现货 | |
| 25 mg | ¥ 10,900 | 现货 | |
| 50 mg | ¥ 14,800 | 现货 | |
| 100 mg | ¥ 19,800 | 现货 |
Vorsetuzumab 相关产品
| 产品描述 | Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a monoclonal antibody targeting the CD70 antibody. Vorsetuzumab has anticancer activity and can enhance the macrophage-associated phagocytosis of kidney cancer cells and inhibit Burkitt lymphoma. |
| 体外活性 | 体外实验中,vorsetuzumab(10 μg/mL;2 h)增强了巨噬细胞对肾癌细胞的依赖性吞噬作用[1]。Vorsetuzumab(10 μg/mL;2 h)可进一步开发为针对人类CD70/KWAR23的双特异性抗体。结果表明,KWAR23在四种肾癌细胞系(RCC4、RCC10、TK10和Caki-1)中适度诱导了巨噬细胞的吞噬作用[1]。 |
| 体内活性 | 在SRG小鼠中,vorsetuzumab(10 mg/kg;i.p.;每隔一天;共12天)抑制了Burkitt's淋巴瘤细胞的增长[1]。 |
| 别名 | 沃瑟妥珠单抗, SGN-70 |
| 分子量 | 146.1 kDa |
| CAS No. | 1165740-62-4 |
| 存储 | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
评论内容